Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Race Oncology Ltd. ( (AU:RAC) ) is now available.
Race Oncology Ltd has issued a letter to eligible Optionholders regarding the exercise of May 2026 piggyback options, addressing frequently asked questions and providing guidance on the process. The early exercise of these options allows the company to commit to new programs sooner, potentially impacting its operational timeline and strategic initiatives positively.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company focused on cancer care. Its lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent with demonstrated therapeutic activity and a well-characterized safety profile. The company is advancing a proprietary formulation, RC220, targeting unmet needs in oncology, particularly in combination with anthracycline for enhanced anticancer activity and cardioprotection. Race Oncology is exploring partnerships and collaborations to accelerate access to RC220 globally.
Average Trading Volume: 430,290
Technical Sentiment Signal: Buy
Current Market Cap: A$733.8M
For an in-depth examination of RAC stock, go to TipRanks’ Overview page.